Indian startup Pharmarack eyes VC funds for pharmacy software offer


Indian firm Pharmarack Technologies said it hopes to land $2 million in venture capital to fund development of an online order and inventory management system for pharmacies and distributors in India.

Industry publication VCCircle cited Pradyumn Singh, CEO of Pharmarack, as saying that existing investor Unicorn India Ventures and others are in late-stage talks on the funds.

“While the existing investors have agreed to put in a part of the targeted amount, we are also in talks with a few marquee venture capital firms. We expect to close the round by the end of June,” Singh told the publication.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

India's pharmacy and drug distribution network is highly fragmented with a noticeable absence of nationwide chain operations that makes tracking products and inventory management difficult.

Founder Singh and partners want to offer the software across players in the industry as a way to keep track in real-time via web and mobile versions, telling VCCircle that most companies in India’s pharma sector lack detailed reports on what happens to product after manufacturing--often leading to poor inventor management and uncertain manufacturing schedules.

The software is now in use in the Maharashtra state cities of Mumbai, Pune, Thane and Nashik; the company aims to be in 35 cities by the end of the year with a monthly cost for users set to be around INR4,000 ($69) a month.

- here's the story from VCCircle


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.